# Turn Therapeutics Inc. (TTRX) fundamentals

Data as of 2026-11-11. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.92, market value $301 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Turn Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 53.3×**. The shares trade at 53.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -68.2%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -71.4%**. Earnings per share fell 71.4%.

## Financial health
- **Current ratio: 0.87** (quick 0.87). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Turn Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 143.5%** (YTD 148.5%, 3-mo 2.0%). The shares are up 143.5% over twelve months including dividends.
- **From 52-week high: -39.7%** (286.0% above the low). Trading 40% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 1.42** (volatility 100%). Beta of 1.42 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TTRX · Page: https://foliofundamentals.com/stocks/ttrx

Not investment advice.